Outreach visits by clinical pharmacists improve screening for the metabolic syndrome among mentally ill patients

References

• Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4–14.
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008;10:788–97.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67 Suppl 9;discussion 36–42.
   Google Scholar
• Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L’Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A nested case–control study. Pharmacotherapy 2007;27: 27–35.
   PubMed Web of Science ®Google Scholar
• Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17:460–6.
   PubMed Web of Science ®Google Scholar
• Taylor V, McQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry 2006;67: 1034–41.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412–24.
   PubMed Web of Science ®Google Scholar
• Hasnain M, Vieweg WVR, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 2009;3:5–15.
   PubMedGoogle Scholar
• Kreyenbuhl J, Medoff DR, Seliger SL, Dixon LB. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. Schizophr Res 2008;101:256–65.
   PubMedGoogle Scholar
• Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta- analysis. Neuropsychopharmacology 2010;35:1520–30.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drug and obesity and diabetes. J Clin Psychiatry 2004;65:267–72.
   PubMed Web of Science ®Google Scholar
• Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32:1037–42.
   PubMed Web of Science ®Google Scholar
• Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17–24.
   PubMed Web of Science ®Google Scholar
• Hakkennes S, Dodd K. Guideline implementation in allied health professions: A systematic review of the literature. Qual Saf Health Care 2008;17:296–300.
   PubMed Web of Science ®Google Scholar
• Sketris IS, Langille Ingram EM, Lummis HL. Strategic opportunities for effective optimal prescribing and medication management. Can J Clin Pharmacol 2009;16:103–25.
   PubMedGoogle Scholar
• Grol R, Grimshaw J. From best evidence to best practice: Effective implementation of change in patients’ care. Lancet 2003;362: 1225–30.
   PubMed Web of Science ®Google Scholar
• Prior M, Guerin M, Grimmer-Somers K. The effectiveness of clinical guideline implementation strategies—A synthesis of systematic review findings. J Eval Clin Pract 2008;14:888–97.
   PubMed Web of Science ®Google Scholar
• O’Brien MA, Rogers S, Jamtvedt G, O’Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: Effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No. CD000409. DOI: 10.1002/14651858.CD000409.pub2.
   Google Scholar
• Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF worldwide definition of the metabolic syndrome. The International Diabetes Federation, Belgium, 2006.
   Google Scholar
• Duclos A, Voirin N. The p-control chart: A tool for care improvement. Int J Qual Health Care 2010;22:402–407.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P. Screening for the metabolic syndrome in community psychiatric prescribed antipsychotics: A quality improvement programme. Acta Psychiatr Scand 2008;118: 26–33.
   PubMed Web of Science ®Google Scholar
• Krane-Gartiser K, Breum L, Glümrr C, Linneberg A, Madsen M, Køster A, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 2011;65:345–52.
   PubMed Web of Science ®Google Scholar
• Minnigan H, Chisholm CD. Conflict of interest in the physician interface with the biomedical industry. E Med Clin N Amer 2006;4: 671–85.
   Google Scholar
• Campo K, De Staebel O, Gijsbrechts E, van Waterschoot W. Physician's decision process for drug prescription and the impact of pharmaceutical marketing mix instruments. Health Mark Quar 2005;2:73–107.
   Google Scholar
• Vainiomaki M, Helve O, Vuorenkoski L. A national survey on the effect of pharmaceutical promotion on medical students. Med Teach 2004;6:630–4.
   Google Scholar
• Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior?A randomized trial. Am J Med 2005;118:881–4.
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen TM. Outcomes of Nordic mental health systems: Life expectancy of patients with mental disorders. Br J Psychiatry 2011;199: 453–8.
   PubMed Web of Science ®Google Scholar
• Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund- Udenaes M, Toss H, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or Older. Arch Intern Med 2009;169:894–900.
   PubMed Web of Science ®Google Scholar
• Hellström LM, Bondesson A, Höglund P. Impact of the Lund Integrated Medicines Management (LIMM) model on medication appropriateness and drug-related hospital revisits. Eur J Clin Pharmacol 2011;67:741–52.
   PubMed Web of Science ®Google Scholar